Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Details 詳細情報について

• CRID

  1360576121650170752

• DOI

  10.1016/s2213-8587(20)30369-7

• ISSN

  22138587

• Web Site

  https://api.elsevier.com/content/article/PII:S2213858720303697?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S2213858720303697?httpAccept=text/plain

• Data Source

  • Crossref